As of November 6, 2026, Avalyn Pharma Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 16, 2026 (Form 8-K, September 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Avalyn Pharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Avalyn Pharma Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-16. Every row below is cited to the filing it comes from, and this page adds each new change as Avalyn Pharma Inc. files it.
Also on the record for Avalyn Pharma Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by Novo Holdings A/S | 8.8% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G, by Norwest Venture Partners XV, LP | 5.1% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 13.2% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13D, by SR One Capital Management, LLC | 7.5% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13D, by SUVRETTA CAPITAL MANAGEMENT, LLC | 5.6% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G, by Perceptive Advisors LLC | 6% of the class | 5%+ stakes | Source |
| May 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 11.5% of the class | 5%+ stakes | Source |
| April 30, 2026 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| April 29, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| April 23, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| April 8, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs Avalyn Pharma Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Avalyn Pharma Inc. and the records around it.
Avalyn Pharma Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- SR One Capital Management, LLC also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Zenas BioPharma, Inc. (Aug 2026), Veradermics, Inc. (Aug 2026)
- Novo Holdings A/S also filed stake reports on 11 other companies: Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), MAPLIGHT THERAPEUTICS, INC. (Jul 2026)
- SUVRETTA CAPITAL MANAGEMENT, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Avalyn Pharma Inc.
Get an email when Avalyn Pharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Avalyn Pharma Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Avalyn Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avalyn Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-16 | Reported | not named in the filing | 8-K, 2026-09-16 |
New leaders reset buying decisions — get the Full Report on Avalyn Pharma Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Avalyn Pharma Inc., with the record behind each one.
Find candidates like senior executive at Avalyn Pharma Inc.Every change, in the filing's words
Reported
Grants made to continuing non-employee directors following the Company's annual meeting of stockholders each year vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting of stockholders, provided that all vesting will cease if the director ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
- Appointment of Director On September 15, 2026 (the "Effective Date"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Avalyn Pharma Inc. (the "Company"), the Board appointed Robert Meyer, M.D. to the Board as a Class II director for an initial term expiring at the annual meeting of stockholders in 2028.
- The Board determined that Dr. Meyer is independent under the listing standards of Nasdaq.
- From January 2018 to October 2024, Dr. Meyer was a principal of the Drug and Biologic Products team at Greenleaf Health Inc., a U.S. Food and Drug Administration, or FDA, strategic consulting company (later acquired by Eliquent Life Sciences).
- He was an associate professor of Public Health Sciences at the University of Virginia School of Medicine from March 2013 to December 2017, where he also served as the director of the Virginia Center for Translational and Regulatory Sciences.
- Prior to joining the faculty at the University of Virginia, Dr. Meyer joined Merck & Co., Inc. in October 2007 and served as Vice President and Head of Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories from November 2009 until January 2013.
Tools for this story
Each opens in a new tab, filled in for Avalyn Pharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.